Medical/Pharmaceuticals

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

GAITHERSBURG, Md., May 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disease...

2024-05-08 04:20 374

Research Results on Jolly Good's Medical VR Will Be Presented for the First Time in the U.S. - Revealing Training VR for HALO Procedures at Large-Scale VR Seminar, SAEM2024

BROOKLINE, Mass., May 7, 2024 /PRNewswire/ -- Jolly Good US Inc. is proud to announce the groundbreaking debut of research findings on its Medical Virtual Reality (VR) platform inthe United States. This unveiling will take place at the annual meeting of the Society for Academic Emergency Medicine...

2024-05-08 02:00 594

Seragon Completes Pre-Clinical Study of Aging Intervention Candidate SRN-901

IRVINE, Calif., May 7, 2024 /PRNewswire/ -- Seragon Biosciences, Inc. today announced the completion of a pre-clinical study on its novel anti-aging candidate, SRN-901. This pivotal study, conducted in mice, was undertaken to evaluate the impact of SRN-901 on aging as well as various health marke...

2024-05-07 22:10 641

FDA Grants Orphan Drug Designation to 9MW2821

SHANGHAI, May 7, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Adminis...

2024-05-07 22:00 541

Meihua International Medical Technologies Co., Ltd. to Present at the Emerging Growth Conference on May 9, 2024

Meihua International Medical Technologies Co., Ltd. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. YANGZHOU, China, May 7, 2024 /PRNewswire/ -- Meihua International Medical Tech...

2024-05-07 21:08 679

Imaging Endpoints Unveils New Initiative with Revolution Endpoints™, an Investment Subsidiary to Accelerate Innovation and Growth

SCOTTSDALE, Ariz., May 7, 2024 /PRNewswire/ -- Imaging Endpoints (IE), a global leader in Imaging CRO technologies and services, has announced the formation of a new subsidiary, Revolution Endpoints, focused on leveraging the Company's strong leadership and financial position to acquire synergist...

2024-05-07 21:00 652

/C O R R E C T I O N -- The Adecco Group/

In the news release, AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange, issued07-May-2024 by The Adecco Group over PR Newswire, we are advised by the client that the headline should read "The Adecco Group: Q1 24 Results" rather than "[AD HOC ANNOUNCEMENT pursuant to Art....

2024-05-07 18:17 1368

Sciwind Biosciences and HK inno.N Corporation Announce Licensing and Partnership Agreement for Ecnoglutide Injection (XW003) in South Korea

HANGZHOU, China and SEOUL, South Korea, May 7, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation, a South Korean commercial stage pharmaceutical company (KOSDAQ: 195940),...

2024-05-07 15:00 743

2024 World Brain Day Dedicated to Brain Health and Prevention

LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place onMonday, July 22. The goal is to raise critical awareness to prevent brain disease in all corners of t...

2024-05-07 14:45 267

GC Genome to Present New Clinical Data on Colorectal Cancer Detection at the ASCO Annual Meeting 2024

YONGIN, South Korea, May 7, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual ...

2024-05-07 13:27 837

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC)as Monotherapy for Advanced Gastric Cancer

SAN FRANCISCO and SUZHOU, China, May 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...

2024-05-07 08:12 942

HTL Biotechnology, market leader in biopolymers, acquires the Modern Meadow's human recombinant collagen platform for beauty and biomedical applications

JAVENÉ, France, May 6, 2024 /PRNewswire/ -- HTL Biotechnology strengthens its position as a global leader in the production and development of pharmaceutical-grade biopolymers by acquiring the beauty and biomedical division of American company Modern Meadow (Nutley, NJ). Notably, this acquisitio...

2024-05-07 07:00 864

ThinkCyte Launches New Website and Showcases VisionSortTM at Global Events

TOKYO, May 7, 2024 /PRNewswire/ -- ThinkCyte today announced that it will be presenting at three major international scientific conferences in the first week of May and the launch of itsupdated website. The company will have a presence at the American Society for Immunology (AAI) fromMay 3rd to 7...

2024-05-06 23:25 929

Datasea Pre-Announces Estimated Revenue of $12.5 Million for April 2024 Supporting its Prior Revenue Guidance of $86 Million for Fiscal 2024

DTSS on Track to Achieve Record Revenue for Fiscal 2024 as it Further Penetrates China's$528 Billion 5G Market BEIJING, May 6, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada and engaged in innovative business seg...

2024-05-06 22:00 1277

PolyU researchers create 2D all-organic perovskites and demonstrate potential use in 2D electronics

HONG KONG, May 6, 2024 /PRNewswire/ -- Perovskites are among the most researched topics in materials science. Recently, a research team led byProf. LOH Kian Ping, Chair Professor of Materials Physics and Chemistry and Global STEM Professor of the Department of Applied Physics of The Hong Kong Po...

2024-05-06 11:56 960

Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting

SUZHOU, China, May 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from the clinical study conducted inChina (JSKN003-102) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, will be presente...

2024-05-06 10:25 1673

World Lupus Federation Global Survey Finds 91% of People with Lupus Report Using Oral Steroids to Treat Lupus

Global public urged to share survey results and lupus facts on May 10 for World Lupus Day WASHINGTON, May 6, 2024 /PRNewswire/ -- A recent global survey conducted by the World Lupus Federation reported that 91% of survey respondents were taking or have taken oral steroids to treat their lupus. O...

2024-05-06 08:00 1030

VYNDAMAX® (tafamidis) PBS-listed for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I-II heart failure

* VYNDAMAX has been listed on the Pharmaceutical Benefits Scheme (PBS) for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM)with New York Heart Association (NYHA) Class I-II heart failure.[1] * ATTR-CM is a debilitating and often fatal condition that l...

2024-05-04 18:00 2140

United Imaging to Unveil Industry-Leading MRI Advancements at ISMRM 2024

Ultra-high-field technology, ultra-high-gradient technology, and advances in artificial intelligence take center stage. SHANGHAI, May 4, 2024 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, will unveil its latest MRI technolog...

2024-05-04 09:00 3048

HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease

* HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study. * Tanfanercept demonstrated statistically significant improvement on the secondary outcome measure, Schirmer testing...

2024-05-03 19:00 1892
12345 ... 577